Diagnosis and management of leukocytoclastic vasculitis

被引:1
作者
Paolo Fraticelli
Devis Benfaremo
Armando Gabrielli
机构
[1] Università Politecnica Delle Marche,Dipartimento Di Scienze Cliniche E Molecolari, Clinica Medica
来源
Internal and Emergency Medicine | 2021年 / 16卷
关键词
Leukocytoclastic vasculitis; Small vessel vasculitis; Cryoglobulinemic vasculitis; IgA vasculitis; Hypocomplementemic urticarial vasculitis;
D O I
暂无
中图分类号
学科分类号
摘要
Leukocytoclastic vasculitis (LCV) is a histopathologic description of a common form of small vessel vasculitis (SVV), that can be found in various types of vasculitis affecting the skin and internal organs. The leading clinical presentation of LCV is palpable purpura and the diagnosis relies on histopathological examination, in which the inflammatory infiltrate is composed of neutrophils with fibrinoid necrosis and disintegration of nuclei into fragments (“leukocytoclasia”). Several medications can cause LCV, as well as infections, or malignancy. Among systemic diseases, the most frequently associated with LCV are ANCA-associated vasculitides, connective tissue diseases, cryoglobulinemic vasculitis, IgA vasculitis (formerly known as Henoch–Schonlein purpura) and hypocomplementemic urticarial vasculitis (HUV). When LCV is suspected, an extensive workout is usually necessary to determine whether the process is skin-limited, or expression of a systemic vasculitis or disease. A comprehensive history and detailed physical examination must be performed; platelet count, renal function and urinalysis, serological tests for hepatitis B and C viruses, autoantibodies (anti-nuclear antibodies and anti-neutrophil cytoplasmic antibodies), complement fractions and IgA staining in biopsy specimens are part of the usual workout of LCV. The treatment is mainly focused on symptom management, based on rest (avoiding standing or walking), low dose corticosteroids, colchicine or different unproven therapies, if skin-limited. When a medication is the cause, the prognosis is favorable and the discontinuation of the culprit drug is usually resolutive. Conversely, when a systemic vasculitis is the cause of LCV, higher doses of corticosteroids or immunosuppressive agents are required, according to the severity of organ involvement and the underlying associated disease.
引用
收藏
页码:831 / 841
页数:10
相关论文
共 220 条
[1]  
Caproni M(2019)An update on the nomenclature for cutaneous vasculitis Curr Opin Rheumatol 31 46-52
[2]  
Verdelli A(2013)2012 revised International Chapel hill consensus conference nomenclature of vasculitides Arthritis Rheum 65 1-11
[3]  
Jennette JC(2018)Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides Arthritis Rheumatol 70 171-184
[4]  
Falk RJ(2010)The histological assessment of cutaneous vasculitis Histopathology 56 3-23
[5]  
Bacon PA(1998)Primary vasculitis in a Norwegian community hospital: a retrospective study Clin Rheumatol 17 364-368
[6]  
Basu N(1999)Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schonlein purpura in adults Semin Arthritis Rheum 28 404-412
[7]  
Cid MC(2014)Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in olmsted county, minnesota Mayo Clin Proc 89 1515-1524
[8]  
Ferrario F(1998)Cutaneous vasculitis in children and adults: Associated diseases and etiologic factors in 303 patients Medicine (Baltimore) 77 403-418
[9]  
Sunderkötter CH(2016)Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: a retrospective study in 112 patients Med (United States) 95 e4238-82
[10]  
Zelger B(2017)Clinical study on single-organ cutaneous small vessels vasculitis (SoCSVV) Med (United States) 96 e6376-315